Drugs by condition
Drugs approved for colorectal cancer
Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
27
Still marketed, NDA or BLA
Drug classes
9
Novel drugs
17
New molecular entities and new biologics
In development
40+
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for colorectal cancer.
- Vykoura (Leucovorin Calcium) · Avyxa Holdings Feb 3, 2026
- Keytruda Qlex (Pembrolizumab, Berahyaluronidase Alfa-Pmph) · Merck Sharp Dohme NovelAccelerated approvalPriority reviewSep 19, 2025
- Jobevne (Bevacizumab-Nwgd) · Biocon Biologics INC Apr 9, 2025
- Opdivo Qvantig (Nivolumab, Hyaluronidase-Nvhy) · Bristol-Myers Squibb Accelerated approvalDec 27, 2024
- Fruzaqla (Fruquintinib) · Takeda Pharms USA NovelPriority reviewNov 8, 2023
All approved drugs for colorectal cancer, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 45 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Vascular Endothelial Growth Factor Inhibitor (7)
- Zaltrap Ziv-Aflibercept · Sanofi Aventis US · 2012
- Avastin Bevacizumab · Genentech · 2004
- Jobevne Bevacizumab-Nwgd · Biocon Biologics INC · 2025
- Vegzelma Bevacizumab-Adcd · Celltrion · 2022
- Alymsys Bevacizumab-Maly · Amneal Pharms LLC · 2022
- Zirabev Bevacizumab-Bvzr · Pfizer INC · 2019
- Mvasi Bevacizumab-Awwb · Amgen INC · 2017
Endoglycosidase (2)
- Keytruda Qlex Pembrolizumab, Berahyaluronidase Alfa-Pmph · Merck Sharp Dohme · 2025
- Opdivo Qvantig Nivolumab, Hyaluronidase-Nvhy · Bristol-Myers Squibb · 2024
Programmed Death Receptor-1 Blocking Antibody (2)
Epidermal Growth Factor Receptor Antagonist (2)
Kinase Inhibitor (1)
- Tukysa Tucatinib · Seagen · 2020
Nucleoside Analog Antiviral (1)
- Lonsurf Tipiracil Hydrochloride, Trifluridine · Taiho Oncology · 2015
Vascular Endothelial Growth Factor Receptor 2 Antagonist (1)
- Cyramza Ramucirumab · Eli Lilly and CO · 2014
CTLA-4-directed Blocking Antibody (1)
- Yervoy Ipilimumab · Bristol Myers Squibb · 2011
Class not listed in FDA's data (10)
- Fruzaqla Fruquintinib · Takeda Pharms USA · 2023
- Lumakras Sotorasib · Amgen INC · 2021
- Braftovi Encorafenib · Array Biopharma INC · 2018
- Tafinlar Dabrafenib Mesylate · Novartis · 2013
- Mekinist Trametinib Dimethyl Sulfoxide · Novartis · 2013
- Stivarga Regorafenib · Bayer Hlthcare · 2012
- Vykoura Leucovorin Calcium · Avyxa Holdings · 2026
- Mekinist Trametinib, Trametinib Dimethyl Sulfoxide · Novartis · 2023
- Tafinlar Dabrafenib Mesylate · Novartis · 2023
- Khapzory Levoleucovorin · Acrotech Biopharma · 2018
Drugs in development for colorectal cancer
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- SHR-A1811Trastuzumab RezetecanPhase 327 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- Telisotuzumab AdizutecanABBV-400Phase 316 trials
AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer
- AK117Phase 314 trials
Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- Anlotinib hydrochlorideAL3818, CatequentenibPhase 312 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Alveolar Soft Part Sarcoma, Metastatic Colorectal Cancer, Endometrial Neoplasms
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- ZanzalintinibXL092Phase 311 trials
Exelixis · Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- JAB-21822Glecirasib Citrate, KRAS G12C inhibitorPhase 310 trials
Allist Pharmaceuticals, Inc. · Non-small Cell Lung Cancer, KRAS P.G12C, Solid Tumor
- PD-1 monoclonal antibodyPhase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
- TucidinostatChidamide, HBI-8000Phase 39 trials
Chipscreen Biosciences, Ltd. · Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy, Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
- LBL-007AlcestobartPhase 38 trials
BeOne Medicines (BeiGene) · Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer, Non Small Cell Lung Cancer, Non-small Cell Lung Cancer
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
- RC148Phase 38 trials
RemeGen Co., Ltd. · Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations, Solid Tumor, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
- IBI363Phase 37 trials
Innovent Biologics (Suzhou) Co. Ltd. · Melanoma, Colorectal Cancer, Resectable Stage II-III Non-small Cell Lung Cancer
- JMT101Phase 37 trials
Shanghai JMT-Bio Inc. · Local Advanced or Metastatic NSCLC, Recurrent or Metastatic Nasopharyngeal Cancer, Patients Who Have Experienced Treatment Failure at Least Second-line Chemotherapy
- JSKN003Phase 37 trials
Shanghai JMT-Bio Inc. · HER2-positive Colorectal Cancer, Advanced Solid Tumor, HER2-positive Gastric Cancer
- OleclumabMEDI9447Phase 37 trials
AstraZeneca · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Metastatic Microsatellite-stable Colorectal Cancer
- PucotenlimabHX008Phase 36 trials
Lepu Biopharma Co., Ltd. · Head and Neck Squamous Cell Carcinoma, Melanoma, Hepatocellular Carcinoma
- Supportive care measuresPhase 36 trials
Merck & Co. · Esophageal Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
1 discontinued brand-name drugs whose label still names it
- Xeloda Capecitabine
More on colorectal cancer: recruiting trials · published research
Related in oncology: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Prostate cancer · Melanoma · Ovarian cancer · Pancreatic cancer · Bladder and urothelial cancer · Kidney cancer (renal cell carcinoma) · Liver cancer (hepatocellular carcinoma)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.